Printer Friendly

Affinity Biologicals launches Factor VIII, Factor IX Deficient plasma products in Canada, Europe.

M2 PHARMA-September 1, 2014-Affinity Biologicals launches Factor VIII, Factor IX Deficient plasma products in Canada, Europe

(C)2014 M2 COMMUNICATIONS

1 September 2014 - Canadian biological diagnostic and research products maker Affinity Biologicals Inc said Friday it had recently introduced a new range of plasmas, including the Factor VIII Deficient and the Factor IX Deficient plasmas, in Canada and Europe.

The products, cleared by Health Canada and CE-marked, are intended for diagnostic use and hemostasis research.

Specifically, the VisuDep-F Frozen Factor VIII Deficient Plasma is developed to be used as a substrate plasma in the quantitative identification of Factor VIII activity in citrated plasmas using a clot-based assay. The plasma product helps detect FVIII insufficiency for the diagnosis of haemophilia A.

Similarly, the VisuDep-F Frozen Factor IX Deficient Plasma is developed for use as a substrate plasma in the quantitative detection of Factor IX activity in citrated plasmas utilising a clot-based assay. The plasma product identifies low activity of Factor IX for the detection of haemophilia B.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2014 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Geographic Code:1CANA
Date:Sep 1, 2014
Words:177
Previous Article:Dako introduces HER2 IQFISH pharmDx assay in EU.
Next Article:Comercial Rafer invests in Spanish bacterial genomics specialist Era7 Bioinformatics.
Topics:

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |